Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Methodological standard

Draft standard: bacterial endotoxin testing of peptide presentations

Consultation on the draft standard for bacterial endotoxin testing of peptide presentations, which specifies the performance a determination must achieve and the interference testing required before a result can be interpreted. The draft records that an…

Document identifier
CEI-CP-014
Series
Public comment period
Version
1.0
Published
23 Nov 2025
Last reviewed
23 Nov 2025
Next review
23 Nov 2026
Identifier
10.71829/cei.cp.14
Certainty
Not rated
Cycle
2025 Q4
Window
12 Oct 2025 – 09 Nov 2025
Status
Closed
Submissions
12

§1Consultation and window

§1.1Window

Opened
12 October 2025
Closed
9 November 2025
Duration
28 days
Status
Closed — the disposition is published
Document under consultation
Standard CEI-MS-05
Submissions received
12

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Are the interference-testing requirements proportionate for peptide matrices at the concentrations typically presented?
  2. Should the standard specify a limit, or state performance and leave the limit to the intended route of administration?
  3. Does the standard state clearly enough that a conformant endotoxin result says nothing about sterility?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The standard was amended before ratification. It states performance and declines to set a universal limit, and it now carries an explicit statement that endotoxin content and sterility are separate determinations answering separate questions.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.